Wilmington Healthcare appoints new Commercial Director
June 26, 2018 | Med Tech, Wilmington Healthcare, healthcare
Healthcare intelligence provider Wilmington Healthcare, which incorporates HSJ, Binley’s, OnMedica and Wellards, has appointed Sue Plant as Commercial Director for MedTech.
Wilmington Healthcare appoints new Commercial Director
Healthcare intelligence provider Wilmington Healthcare, which incorporates HSJ, Binley’s, OnMedica and Wellards, has appointed Sue Plant as Commercial Director for MedTech.
In her new post, Sue will lead Wilmington Healthcare’s MedTech services, which include healthcare data, education, information and analytics. She will also oversee a number of key accounts.
Having worked in sales, marketing and business management roles in healthcare for nearly 20 years, Sue has joined Wilmington Healthcare from Veeva Systems, where she was Global Director for Customer Success.
Prior to that, she was Global Strategic Account Director for Zinc Ahead Ltd, where she was the global point of contact for key corporate contacts. The company was acquired by Veeva in September 2015.
Other roles that Sue has held include Product Manager, Anaesthesia & Critical Care, UK, for Baxter Healthcare UK, responsible for the company’s pharmaceutical and medical devices portfolio.
Gareth Thomas, Managing Director of Wilmington Healthcare, said: “Having worked in sales, marketing and business management roles within the healthcare industry for nearly 20 years, Sue will be a great asset to the MedTech team.
“Medtech is a key sector within our portfolio and Sue will play a key role in helping our clients to better understand the challenges they face, exploit their knowledge and expertise, and optimise their business success.”
Ends
Notes to Editors
For more information, please contact: Andrew Baud and Catherine McNulty, Tala, +44 (0) 20 3397 3383 or +44 (0) 7775 715775, Email: andrew.baud@teamtala.com /catherine.mcnulty@teamtala.com
About Wilmington Healthcare and Wilmington plc
Wilmington Healthcare within the UK, incorporates HSJ, Binley’s, OnMedica, and Wellards . A part of Wilmington plc whose group companies help clients turn data into actionable business benefit, Wilmington Healthcare focuses on working with its customers to turn its high quality healthcare data into meaningful intelligence to support their business objectives and the improvement of healthcare. For further information, visit www.wilmingtonhealthcare.com.
Wilmington plc focuses on three key knowledge areas: Risk & Compliance, Professional, and Healthcare. Wilmington’s businesses enable professionals and their organisations to perform better by providing quality, relevant and reliable information, education and networking. For more information on Wilmington plc visit www.wilmingtonplc.com.
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...